India · Delayed Price · Currency is INR Rainbow Children's Medicare Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw 12% revenue growth and strong new unit ramp-up, despite seasonal volume softness and increased competition. Occupancy was 47.2%, with a focus on driving this to 55-60% next year through digital, marketing, and specialty expansion. Cash reserves and capex plans remain robust.
-
Q2 FY26 saw 6.5% revenue growth but lower occupancy due to seasonality, with strong specialty and IVF growth. Integration of new acquisitions and hospital expansions continue, supported by a robust net cash position and a 20% revenue CAGR target over the next 2–3 years.
-
Revenue grew 7% YoY to INR 353 crores, with EBITDA up 11% and PAT up 35%. Expansion continued via acquisition and new projects, while mature hospitals saw muted volumes but strong specialty mix. Guidance remains for late teens to 20% revenue growth, with robust cash reserves and asset-light expansion.
Fiscal Year 2025
-
Q4 FY25 saw 8.5% revenue growth and 10.7% PAT growth, with strong cash generation and robust expansion plans. Mature hospitals maintained high occupancy, IVF revenue surged, and margin guidance remains at 25%+ despite new bed additions.
-
Q3 FY25 delivered 18.5% revenue growth and 14% EBITDA growth year-over-year, with strong performance from both mature and new hospitals. Expansion plans remain on track, though international business faces headwinds and new projects like Gurgaon will be asset-heavy.
-
Q2 FY25 saw 25.5% revenue growth and record profitability, driven by strong performance in mature and new hospitals, robust IVF growth, and disciplined cost management. Expansion continues with 380 new beds planned, while international business faces geopolitical headwinds.
-
Q1 FY25 saw 15% revenue growth and strong operational metrics, with new hospitals expanding capacity but impacting margins due to higher costs. Occupancy and patient volumes improved, and margin recovery is expected as new units ramp up and break even.